GeraldStevenFalchookMD

Oncology • Denver, CO

Oncologist at Sarah Cannon Research

Join to view full profile

Dr. Falchook is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Falchook's full profile

Already have an account?

Office
1800 N Williams St
Ste 300
Denver, CO 80218
Phone+1 720-754-2610

Fax+1 720-754-2659
Is this information wrong?

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
Baylor College of MedicineResidency, Internal Medicine, 2001 - 2004
Louisiana State University School of Medicine in New OrleansClass of 2001

Certifications & Licensure

CO State Medical License 2004 - 2025
TX State Medical License 2004 - 2015
PA State Medical License 2004 - 2004
American Board of Internal Medicine Medical Oncology

Clinical Trials

Bevacizumab and Bortezomib in Patients With Advanced Malignancy Start of enrollment: 2007 Jan 01
Completed
Phase 1
Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients Start of enrollment: 2005 Jan 01
Completed
Phase 1
Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer Start of enrollment: 2007 Aug 01
Completed
Phase 1
Bevacizumab in Multiple Phase I Combinations Start of enrollment: 2007 Oct 10
Completed
Phase 1
First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors Start of enrollment: 2009 Nov 30
Completed
Phase 1
First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors Start of enrollment: 2010 Apr 01
Terminated
Phase 1
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors Start of enrollment: 2013 Oct 01
Completed
Phase 1
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Start of enrollment: 2014 Jan 01
Completed
Phase 1
Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas Start of enrollment: 2016 Jan 01
Completed
Phase 1, Phase 2
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors Start of enrollment: 2016 Jun 16
Completed
Phase 1
Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer Start of enrollment: 2016 Jun 29
Completed
Phase 1
Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer Start of enrollment: 2017 Feb 22
Completed
Phase 2
A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer Start of enrollment: 2017 Sep 18
Completed
Phase 2
Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors Start of enrollment: 2019 Aug 01
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer.
Gerald S Falchook, James Reeves, Sunil Gandhi, David R Spigel, Edward Arrowsmith, Daniel J George, Janet Karlix, Gayle Pouliot, Maureen M Hattersley, Eric T Gangl, Gar...> ;Cancer Immunology, Immunotherapy. 2024 Mar 2
A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors.
Gerald Falchook, Amita Patnaik, Debra L Richardson, R Donald Harvey, Manish R Sharma, Navid Hafez, Erika Hamilton, Sarina A Piha-Paul, Minal Barve, Trisha Wise-Draper,...> ;Clinical Therapeutics. 2024 Mar 1
B7-H3 Inhibitors in Oncology Clinical Trials: A Review.
Martin, J., Feustel, K., Falchook, G.> ;Journal of Immunotherapy and Precision Oncology. 2024 Feb 1
1 citations
Sotorasib with panitumumab in chemotherapy-refractory KRAS-mutated colorectal cancer: a phase 1b trial.
Kuboki, Y., Fakih, M., Strickler, J., Yaeger, R., Masuishi, T., Kim, E., Bestvina, C., Kopetz, S., Falchook, G., Langer, C., Krauss, J., Puri, S., Cardona, P., Chan, E...> ;Nature Medicine. 2024 Jan 1
Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary.
Grace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, Gerald S Falchook, Antoine Italiano, Jürgen Wolf, Adrian G Sacher, Toshiaki Takahashi, Suresh S Ramalingam, Christo...> ;Future Oncology. 2024 Jan 1
2 citations
A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors.
Gerald S Falchook, Jasgit Sachdev, Esteban Rodrigo Imedio, Sanjeev Kumar, Ganesh M Mugundu, Suzanne Jenkins, Juliann Chmielecki, Suzanne Jones, David R Spigel, Melissa...> ;Investigational New Drugs. 2023 Jun 1
14 citations
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With PretreatedG12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100.
Grace K Dy, Ramaswamy Govindan, Vamsidhar Velcheti, Gerald S Falchook, Antoine Italiano, Jürgen Wolf, Adrian G Sacher, Toshiaki Takahashi, Suresh S Ramalingam, Christo...> ;Journal of Clinical Oncology. 2023 Jun 20
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and...
Arvind Dasari, Erika P Hamilton, Gerald S Falchook, Judy S Wang, Daneng Li, Max W Sung, Caly Chien, Shivani Nanda, Christopher Tucci, Marjo Hahka-Kemppinen, Andrew Sco...> ;Investigational New Drugs. 2023 Jun 1
Plain language summary of the development of tepotinib: a treatment for a subtype of non-small cell lung cancer calledexon 14 skipping.
John Hallick, Anne-Marie Baird, Gerald Falchook, Xiuning Le, David Hong, Santiago Viteri, Jo Raskin, Niels Reinmuth, Soetkin Vlassak, Mihaela Militaru, Paul K Paik> ;Future Oncology. 2023 Mar 1
A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors.
Filip Janku, Milind M Javle, Shiraj Sen, Shubham Pant, Lindsay G Bramwell, Vivek Subbiah, Tracey Way, David S Wages, Catherine A Wheeler, Takeaki Suzuki, Kazunori Saek...> ;Cancer. 2023 May 15
4 citations
Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours.
Melissa L Johnson, Judy S Wang, Gerald Falchook, Carol Greenlees, Suzanne Jones, Donald Strickland, Giulia Fabbri, Caroline Kennedy, J Elizabeth Pease, Liz Sainsbury, ...> ;British Journal of Cancer. 2023 May 1
5 citations
Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors.
Aung Naing, Alain P Algazi, Gerald S Falchook, Benjamin C Creelan, John Powderly, Seth Rosen, Minal Barve, Niharika B Mettu, Pierre L Triozzi, John Hamm, Gongfu Zhou, ...> ;Cancer. 2023 Jan 1
17 citations
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors.
Emerson A Lim, Johanna C Bendell, Gerald S Falchook, Todd M Bauer, Charles G Drake, Jennifer H Choe, Daniel J George, Janet L Karlix, Susanna Ulahannan, Kris F Sachsen...> ;Clinical Cancer Research. 2022 Nov 14
22 citations
Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review.
Kavanya Feustel, Gerald S Falchook> ;Journal of Immunotherapy and Precision Oncology. 2022 Aug 1
15 citations
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.
Timothy A Yap, Justin F Gainor, Margaret K Callahan, Gerald S Falchook, Russell K Pachynski, Patricia LoRusso, Shivaani Kummar, Geoffrey T Gibney, Howard A Burris, Sco...> ;Clinical Cancer Research. 2022 Sep 1
45 citations
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-Type TP53.
Mansoor N. Saleh, Manish R. Patel, Todd M. Bauer, Sanjay Goel, Gerald Steven Falchook, Geoffrey I. Shapiro, Ki Y. Chung, Jeffrey R. Infante, Robert M. Conry, Guilherme...> ;Clinical Cancer Research. 2021 Oct 1
564 citations
Sotorasib for Lung Cancers with KRAS p.G12C Mutation.
Ferdinandos Skoulidis, Bob T. Li, Grace K. Dy, Timothy J. Price, Gerald Steven Falchook, Jürgen Wolf, Antoine Italiano, Martin Schuler, Hossein Borghaei, Fabrice Barle...> ;The New England Journal of Medicine. 2021 Jun 4
11 citations
Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose
Wenyuan Xiong, Manja Friese-Hamim, Andreas Johne, Christopher Stroh, Manfred B. Klevesath, Gerald Steven Falchook, David S. Hong, Pascal Girard, Samer El Bawab> ;CPT. 2021 May 1
25 citations
A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.
Gerald Steven Falchook, Marc Peeters, Sylvie Rottey, Luc Dirix, Radka Obermannova, Jonathan Cohen, Ruth Perets, Ronnie Shapira Frommer, Todd M. Bauer, Judy S. Wang, Ri...> ;Investigational New Drugs. 2021 Apr 14
91 citations
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced...
Gerald Steven Falchook, Jeffrey R. Infante, Hendrik-Tobias Arkenau, Manish R. Patel, Emma Dean, Erkut Borazanci, Andrew Brenner, Natalie Cook, Juanita Lopez, Shubham P...> ;Eclinicalmedicine. 2021 Mar 30
5 citations
Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study
Tina Cascone, R.L. Sacks, Ishwaria Mohan Subbiah, Neele Drobnitzky, Sarina Anne Piha-Paul, David S. Hong, KR Hess, Behrang Amini, Tarak Bhatt, Siquing Fu, Aung Naing, ...> ;ESMO Open. 2021 Apr 1
21 citations
A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer.
Manish R. Patel, Gerald Steven Falchook, Kensuke Hamada, Lukas Makris, Johanna C. Bendell> ;Cancer Medicine. 2021 Feb 5
6 citations
Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers.
Filip Janku, Divya Sakamuri, Shumei Kato, Helen J. Huang, S. Greg Call, Aung Naing, Veronica R. Holley, Sapna Pradyuman Patel, Rodabe N. Amaria, Gerald S. Falchook, Sa...> ;Cancer. 2021 Feb 1
46 citations
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer
Danny Rischin, Marta Gil-Martin, Antonio González-Martín, Irene Brana, June Y. Hou, Daniel Cho, Gerald Steven Falchook, Silvia C. Formenti, Salma K. Jabbour, Kathleen ...> ;Gynecologic Oncology. 2020 Nov 1
14 citations
Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Filip Janku, Haeseong Park, S. Greg Call, Kiran Madwani, Yasuhiro Oki, Vivek Subbiah, David S. Hong, Aung Naing, Vivianne Velez-Bravo, Tamara G. Barnes, Fredrick B. Ha...> ;Clinical Cancer Research. 2020 Nov 1
Join now to see all

Journal Articles

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S Hong, Marwan G Fakih, Gregory A Durm, Geoffrey I Shapiro, Gerald S Falchook, Adrian Sacher, Crystal S Denlinger, John C Krauss, Andrew L Coveler, Suresh S Rama..., The New England Journal of Medicine

Lectures

Immune modulation after Toca 511 and Toca FC treatment of colorectal cancer patients.
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020

Authored Content

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020

Press Mentions

Plain Language Summary of the Development of Tepotinib: A Treatment for a Subtype of Non-Small Cell Lung Cancer Called MET Exon 14 SkippingMarch 31st, 2023
Sarah Cannon to Present Latest Cancer Research Insights at 2021 ASCO® Annual MeetingJune 4th, 2021
Sarah Cannon to Present Latest Cancer Research Insights at ASCO®20 Virtual MeetingMay 28th, 2020
Join now to see all